Wheeler's biomanufacturing programs will initially focus on antibody therapeutics. The company's discovery-to-investigational new drug (IND) programs are designed to provide emerging biopharma companies a faster and more predictable path to the clinic.

Wheeler is located in Oklahoma City with pilot labs located inside Alloy's Boston facility. The company will open a 35,000-sq-ft cGMP facility in Oklahoma City late next year and will have preferred access to expand its biomanufacturing offering to commercial scale production in the recently announced 400,000-sq-ft manufacturing complex in the city's Innovation District.

Founded in 2017 and privately funded, Alloy facilitates access to the entire drug discovery community from academic scientists and small and medium biotechs to the largest biopharmas, the company said. Alloy's lead offering is the ATX-Gx platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.

Sana to open new CGT manufacturing facility
Sana Biotechnology has signed a lease to develop a 163,000-sq-ft manufacturing facility in Fremont, CA, to support the manufacture of its late-stage clinical...

Thermo Fisher opens cGMP plasmid DNA manufacturing facility in Calif.
Thermo Fisher Scientific announced it has officially opened its new current good manufacturing practice (cGMP) plasmid DNA manufacturing facility in Carlsbad,...

Vernal Biosciences launches as mRNA manufacturer
Vernal Biosciences has launched as a new mRNA manufacturer, supported by a round of seed funding led by Alloy Therapeutics.

AGTC expands gene therapy manufacturing capabilities
Applied Genetic Technologies (AGTC) has initiated plans to lease a build-to-suit 21,000-sq-ft current good manufacturing practice manufacturing and quality...

Alloy raises $75M to advance biologics discovery platforms
Biotechnology ecosystem company Alloy Therapeutics announced it has closed $75 million in series C funding.